These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38254627)

  • 21. Regulation and tissue-specific expression of δ-aminolevulinic acid synthases in non-syndromic sideroblastic anemias and porphyrias.
    Peoc'h K; Nicolas G; Schmitt C; Mirmiran A; Daher R; Lefebvre T; Gouya L; Karim Z; Puy H
    Mol Genet Metab; 2019 Nov; 128(3):190-197. PubMed ID: 30737140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Porphyria].
    Stölzel U; Stauch T; Kubisch I
    Internist (Berl); 2021 Sep; 62(9):937-951. PubMed ID: 34185109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically important features of porphyrin and heme metabolism and the porphyrias.
    Besur S; Hou W; Schmeltzer P; Bonkovsky HL
    Metabolites; 2014 Nov; 4(4):977-1006. PubMed ID: 25372274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.
    Vera-Yunca D; Serrano-Mendioroz I; Sampedro A; Jericó D; Trocóniz IF; Fontanellas A; Parra-Guillén ZP
    Mol Genet Metab; 2019 Nov; 128(3):367-375. PubMed ID: 30639045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Porphyrias].
    Stölzel U; Stauch T; Doss MO
    Internist (Berl); 2010 Dec; 51(12):1525-33; quiz 1534. PubMed ID: 21104216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietic protoporphyria.
    Lecha M; Puy H; Deybach JC
    Orphanet J Rare Dis; 2009 Sep; 4():19. PubMed ID: 19744342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.
    Clavero S; Bishop DF; Haskins ME; Giger U; Kauppinen R; Desnick RJ
    Hum Mol Genet; 2010 Feb; 19(4):584-96. PubMed ID: 19934113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How I treat erythropoietic protoporphyria and X-linked protoporphyria.
    Leaf RK; Dickey AK
    Blood; 2023 Jun; 141(24):2921-2931. PubMed ID: 36898083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria.
    Vera-Yunca D; Córdoba KM; Parra-Guillen ZP; Jericó D; Fontanellas A; Trocóniz IF
    Br J Pharmacol; 2022 Jul; 179(14):3815-3830. PubMed ID: 35170015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Wang B; Bonkovsky HL; Lim JK; Balwani M
    Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
    Bonkovsky HL; Dixon N; Rudnick S
    Mol Genet Metab; 2019 Nov; 128(3):213-218. PubMed ID: 30987916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematologic aspects of the porphyrias.
    Sassa S
    Int J Hematol; 2000 Jan; 71(1):1-17. PubMed ID: 10729988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model.
    Abitbol M; Puy H; Sabaté JM; Guénet JL; Deybach JC; Montagutelli X
    Physiol Res; 2006; 55 Suppl 2():S93-101. PubMed ID: 17298226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A family with acute intermittent porphyria.
    Billoo AG; Lone SW
    J Coll Physicians Surg Pak; 2008 May; 18(5):316-8. PubMed ID: 18541093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.